OMARON (Piracetam, Cinnarizine) pills

Instructions for OMARON (Piracetam, Cinnarizin)

Description:

White tablets, round, flat cylindrical, with risks on one side and on the faça on both sides; marble surface is allowed.

1 tab
piracetes 400 mg
zinnarisin 25 mg
Auxiliary substances: lactose monogydrate, magnesium carbonate heavy, povidon K30, silicon coloidal dioxide (A-380), calcium stearat, crosspovydon (colly) don CL-M).

ATX codes

N06BX Other psychostimulators and nootropic Piracetam drugs OMARON

Pharmacological groups / Group membership:

A drug OMARON that improves blood circulation and metabolism in the brain

Active substance:

piracetes
zinnarizin

Pharmacy Group:

Notropic drug

Pharmaceuticals:

Combination drug OMARONА with antihypoxic, nootropic and vasodophyxic effect.

Piracetes activate metabolic processes in the brain by strengthening the energy and protein exchange, accelerating the utilization of glucose by cells and increasing their resistance to hypoxia, improving interneuronal transmission to the CNS, improving regional blood flow in ishemiz in the designated zone.

Cinnarisin - selective blockage of slow calcium canals, inhibits the entry of calcium ions into cells and reduces their content in the depos of plaszmolemma, reduces the tone of smooth arteriol musculature, reduces their reaction to bi Cardiovascular agents (epinephrine, norepinephrine, dopamine, angiotensin, vasopressin). It has a vasodilating effect (especially with regard to brain vessels, increasing the antihypoxic action of piracetam) without having a significant effect on AD. It exhibits moderate antihistamine activity, reduces the excitability of the vestibular laser apparatus, Tones the sympathetic nervous system. Improves the elasticity of erythrocyte membranes, their ability to deform, reduces blood viscosity.

Testimonials:

Diseases of the CNS, accompanied by a decrease of intellectual and monetary functions.
As part of the complex therapy:
Insufficiency of brain blood circulation (atherosclerosis of brain vessels, recovery period after ischemic and hemorrhagic stroke);
encephalopathy, post-intoxicative or post-traumatic;
depression;
organo-psychosis syndrome, with the predominance of the signs of asthenia and apamine;
vestibular disturbances;
Menier syndrome;
children's intellectual underdevelopment;
Migraine prevention;
Kinetosis prevention in adults and children.

Method of application, course and dosage:

Inside, during or after the meal.

Adults - 1-2 tab. 3 times/day for 1-3 months, depending on the severity of the disease. Re-treatments are possible - 2-3 times a year.
Children over 5 years - 1-2 tab. 1-2 times/day. Do not apply more than 3 months.
To prevent kinetos: Adults - 1 tab., children over 5 years - 1/2 tab. for 30 min before the start of the journey, with receptions (if necessary) every 6-8 hours.
In case of chronic kidney failure (Creatine clearance 20-80 ml/min) - 1 tab 2 times/day.

Overdose:

Symptoms of overdose, caused mainly by the m-cholino-blocking activity of the zinnarisine, include: Consciousness disorders, vomiting, extraspyramid symptoms, and reduction of blood pressure. After oral use of piracetam at a dose of 75 g, diarrhea was observed with blood and stomach pain.

Treatment: a specific antidote does not exist. In case of overdose, it is necessary to wash the stomach and take activated carbon, conduct symptomatic and supporting therapy. The effectiveness of hemodialysis for piracetam is 50-60%.

Drug Interaction:

At the same time, it is possible to strengthen the sedative action of the means that oppress the activities of the CSN, as well as ethanol, nootropic and antihypertensive means.

Vasodilating agents strengthen the action of the drug. OMARON

Improves the tolerability of antipsychotic drugs and tricyclic antidepressants.OMARON 

When simultaneously used, piracetes amplify the central effects of thyroid hormones (tremors, anxiety, irritability, sleep disorders are possible).
It can strengthen the action of oral anticoagulants.

Side Action:

From the central and peripheral nervous system: motor respite, irritability, sleepiness, depression, asthenia, headache. In some cases, dizziness, ataxia, acute epilepsy, extrapyramid disorders, tremor, unbalanced, reduced ability to concentrate, insomnia, arousal, anxiety, hallucinations, enhancement of sexuality are noted.

On the side of the cardiovascular system: decrease or increase AD.
From the digestive system: dyspeptic phenomena, dryness in the mouth; In some cases - nausea, vomiting, diarrhea, abdominal pain, cholestatic yellows.
On the skin cover side: In some cases dermatitis, itching, skin rash.
From metabolism: body mass increase.
Allergic reactions: angionevrotic swelling.
Others: sweating enhancement; In some cases - wolf-like syndrome, red flat fox.

Contraindications to use:

severe liver failure;

Severe kidney failure (Creatinin clearance less than 20 ml/min);
hemorrhagic stroke; Parkinsonism (including Parkinson's disease);
psychomotor arousal;
Gentington disease;
pregnancy;
lactation period;
Children up to 5 years of age;

lactose intolerability, lactasy insufficiency, glucose-galactic malabsorption syndrome (the drug contains lactose);OMARON 

increased sensitivity to the main and/or auxiliary components of the drug. OMARON

With caution: liver and/or kidney disease, chronic kidney failure (Creatin clearance 20-80 ml/min); Intraocular pressure; porphyria; violation of hemostasis; extensive surgery; heavy bleeding; hyperthyroidism; epilepsy; expressed atherosclerosis of brain vessels; a tendency toward neurotic reactions.

Special Instructions:

For long-term use, liver and kidney function control (especially in patients with chronic renal failure) is recommended.

During the treatment, patients with arterial hypotension may experience a higher reduction in AD.
It is not recommended to use alcohol during treatment.

Doping test results and allergic skin tests may be distorted; 4 days before the examination the drug should be canceled.OMARON 

Impact on the ability to drive vehicles and mechanisms
During treatment, care must be taken when driving vehicles and other potentially dangerous activities requiring increased concentration and rapid psychomotor reactions.

Application for kidney disorders:

Contraindications for severe kidney failure (Creatin clearance less than 20 ml/min).
In case of chronic kidney failure (Creatine clearance 20-80 ml/min) - 1 tab 2 times/day.

Application for liver disorders:

Contraindications for severe liver failure.

Terms of implementation

The drug OMARON is released according to the prescription.OMARON

Application of children:

Children over 5 years - 1-2 tab. 1-2 times/day. Do not apply more than 3 months.

To prevent kinetos: Children older than 5 years - 1/2 tab. 30 minutes before the start of the journey, with receptions (if necessary) every 6-8 hours.
Contraded for children under 5 years of age.

Nozology
Personal disorders and behaviors caused by brain disease, damage or dysfunction
Depressive episode
Recurent depressive disorder
Mixed anxiety and depressive disorder
Non-vegetation
Mental backwardness unspecified
Migren
Toxic encephalopathy
Encephalopathy Unspecified
Vestibular function violations
Menera's Disease
Intrabrain hemorrhage (brain hemorrhage disorder)
Brain Infarction
Cerebral atherosclerosis

Effects of cerebrovascular diseases